Liraglutide, a GLP1-RA, has been approved for treatment of T2D in 2009 by the European Medicines Agency (EMA), and in 2010 by the FDA and for the treatment of obesity in 2014 (FDA) and 2015 (EMA) (Iepsen et al., 2015). This evidence concerns the gene GCG and Obesity.